Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality
It has been discovered that certain selected ethers of probucol, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL cholesterol. These compounds may also improve HDL functionality by (a) increasing clearance of cholesteryl esters, (b) increasing HDL-particle affinity for hepatic cell surface receptors or (c) increasing the half life of apoAI-HDL.
1. A compound of the formula
or its pharmaceutically acceptable salt or prodrug.
2. A compound of the formula:
or its pharmaceutically acceptable salt or prodrug.
3. A method for increasing high density lipoprotein cholesterol level in a host comprising administering an effective amount of the compound of claim 1 .
4. A method to improve the functionality of circulating high density lipoprotein in a host, comprising administering an effective amount of the compound of claim 1 .
5. A method for increasing high density lipoprotein cholesterol level in a host comprising administering an effective amount of the compound of claim 2 .
6. A method to improve the functionality of circulating high density lipoprotein in a host, comprising administering an effective amount of the compound of claim 2 .
7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of
or a pharmaceutically acceptable salt thereof.
8. The pharmaceutical composition of claim 7 further comprising an IBAT inhibitor.
9. The pharmaceutical composition of claim 7 further comprising a statin.
10. The pharmaceutical composition of claim 9 wherein the statin is selected from the group consisting of lovastatin, simvastitin, pravastatin, fluvastatin, and atorvastatin.
11. The pharmaceutical composition of claim 7 further comprising a CETP inhibitor.
12. The pharmaceutical composition of claim 7 further comprising a fibrate.
13. The pharmaceutical composition of claim 7 further comprising nicotinic acid.
14. The pharmaceutical composition of claim 7 further comprising a compound selected from group consisting of probucol, nicotinic acid, platelet aggregation inhibitors, aspirin, coumadin, varapmil, diltiazem, nifedipine, an ACE inhibitor, captopril enalopril, propanalol, terbutalol, labetalol, ibuprofen, indomethacin, fenoprofen, mefenamic acid, flufenamic acid, sulinda, and a corticosteroid.
15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of
or a pharmaceutically acceptable salt thereof.
16. The pharmaceutical composition of claim 15 further comprising a statin.
17. The pharmaceutical composition of claim 16 wherein the statin is selected from the group consisting of lovastatin, simvastitin, pravastatin, fluvastatin, and atorvastatin.
18. The pharmaceutical composition of claim 15 further comprising a CETP inhibitor.
19. The pharmaceutical composition of claim 15 further comprising a fibrate.
20. The pharmaceutical composition of claim 15 further comprising nicotinic acid.
21. The pharmaceutical composition of claim 15 further comprising a compound selected from group consisting of probucol, nicotinic acid, platelet aggregation inhibitors, aspirin, coumadin, varapmil, diltiazem, nifedipine, an ACE inhibitor, captopril enalopril, propanalol, terbutalol, labetalol, ibuprofen, indomethacin, fenoprofen, mefenamic acid, flufenamic acid, sulinda, and a corticosteroid.
22. A method to treat a cardiovascular disease in a subject, which method comprises administering to said subject a therapeutically-effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.
23. The method of claim 22 wherein the cardiovascular disease is atherosclerosis.
24. The method of claim 22 wherein the cardiovascular disease is hypercholesterolemia.
25. A method to treat a cardiovascular disease in a subject, which method comprises administering to said subject a therapeutically-effective amount of a compound of claim 2 or a pharmaceutically acceptable salt thereof.
26. The method of claim 25 wherein the cardiovascular disease is atherosclerosis.
27. The method of claim 25 wherein the cardiovascular disease is hypercholesterolemia.
28. The method of claim 3 wherein the host is a human.
29. The method of claim 4 wherein the host is a human.
30. The method of claim 5 wherein the host is a human.
31. The method of claim 6 wherein the host is a human.
32. The method of claim 22 wherein the subject is a human.
33. The method of claim 25 wherein the subject is a human.